Key statistics
On Monday, argenx SE (1AEA:FRA) closed at 640.00, -20.99% below its 52-week high of 810.00, set on Nov 24, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 635.00 |
|---|---|
| High | 640.00 |
| Low | 635.00 |
| Bid | -- |
| Offer | -- |
| Previous close | 650.00 |
| Average volume | 6.80 |
|---|---|
| Shares outstanding | 61.88m |
| Free float | 6.88m |
| P/E (TTM) | 39.28 |
| Market cap | 47.99bn USD |
| EPS (TTM) | 19.52 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 16:08 GMT.
More ▼
Announcements
- argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
- argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
- argenx to Present at TD Cowen 46th Annual Healthcare Conference
- argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
- argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
- argenx Highlights 2026 Strategic Priorities
- argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
- argenx Announces Leadership Transition Marking Next Evolution of Growth
- argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
- argenx Announces Results of Extraordinary General Meeting of Shareholders
More ▼
